Eagle Pharmaceuticals and Enalare Therapeutics Announce : vi

-- ENA-001, a new chemical entity with a unique mechanism of action, is being developed as an agnostic respiratory stimulant for use in multiple patient...

Related Keywords

Japan , United States , Lisam Wilson , Herm Cukier , National Institute On Drug Abuse , Acacia Pharma Inc , Site Communications Inc , Company Or Enalare , Nasdaq , Company Annual Report On Form , Investor Relations For Eagle Pharmaceuticals Inc , Company Quarterly Report On Form , Eagle Pharmaceuticals Inc , National Institutes Of Health , Biomedical Advanced Research , Human Services , Us Department Of Health , Eagle Pharmaceuticals , Drug Administration , Administration For Strategic Preparedness , Development Authority , Exchange Commission , Enalare Therapeutics Inc , European Medicines Agency , Enalare Therapeutics , Strategic Preparedness , National Institute , Drug Abuse , National Institutes , Scott Tarriff , Chief Executive Officer , Repurposing Drugs , Chemical Threats , Acacia Pharma , Private Securities Litigation Reform Act , Annual Report , Quarterly Report , Site Communications , Safety Information , Nasdaq Egrx , Nc ,